Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Pelage is moving to Phase III clinical trials for PP405, a hair loss treatment, with results to be presented at a medical meeting. Users express skepticism and hope, comparing it to existing treatments like Minoxidil and finasteride, while discussing the potential for new hair growth in previously bald areas.

A 57-year-old man with male pattern hair loss and insulin resistance experienced hair regrowth and weight loss after using tirzepatide, without other hair treatments. Dysregulated glucose metabolism is linked to hair loss, with tirzepatide potentially improving hair density by normalizing insulin resistance.

People are hopeful for a permanent hair loss solution by the 2030s, considering options like hair cloning and treatments like pp405. Synthetic hair transplants have been attempted but are not effective long-term.

New hair loss treatments PP405 and VDPHL01 are discussed with skepticism and hope, alongside existing treatments like minoxidil and finasteride. Users express frustration over limited progress since the 1980s but remain cautiously optimistic.

Developing new hair loss treatments is challenging due to the complexity and cost of trials, and a permanent cure is unlikely soon. Current treatments like Minoxidil and finasteride are used continuously because hair loss is progressive, and future possibilities include gene editing and hair cloning.

PP405, a topical treatment, shows promise for hair growth by activating inactive follicles, with 66% of participants experiencing positive results. The treatment is well-tolerated and may proceed directly to Phase 3 trials, offering a potential alternative to minoxidil and finasteride.

Low testosterone and estradiol may contribute to hair loss, and blocking DHT without sufficient hormone levels might hinder regrowth. The discussion highlights the importance of hormone balance, with some considering supplements and lifestyle changes to support hair health.

The conversation discusses the effectiveness of different versions of Pyrilutamide (KX-826) for hair loss, with skepticism about the cosmetic versions and interest in a new 1.0% version. Some users report success with products from Koshine, while others criticize Pyrilutamide's effectiveness compared to Minoxidil.

Thin, short hairs often appear in areas of hair loss but may not grow fully despite treatments like finasteride. Some users consider additional treatments like microneedling or hair transplants.

The conversation discusses the complexity of reversing hair loss and the need for a treatment that specifically targets DHT levels without affecting other bodily functions. It mentions finasteride as a current treatment but highlights the desire for a solution that works solely on the scalp.

The conversation humorously discusses the idea of cloning oneself for hair transplants, with suggestions of lobotomizing and castrating the clone. It includes various satirical and absurd comments about using clones for personal benefits beyond hair, such as companionship and organ donation.

PP405 is viewed skeptically, with some seeing it as overhyped and potentially ineffective compared to existing treatments like minoxidil and finasteride. While it shows some promise in activating dormant hair follicles, many believe it won't replace hair transplants or significantly outperform current options.

The conversation humorously suggests that elites with full hair are suppressing a hair loss cure to maintain their dating advantage. It mentions treatments like hair systems, hair transplants, and medications such as Minoxidil and finasteride.

Hair loss treatments, including PP405, minoxidil, finasteride, and RU58841, with hopes for future solutions. Participants discuss the emotional impact of hair loss and consider alternatives like hair transplants or acceptance.

A person with low-density hair likely experiencing diffuse thinning. Suggested treatments include finasteride, minoxidil, and dutasteride.

A young man with hypertrichosis has over 95% of his face covered in hair, sparking humorous comments about hair loss treatments like minoxidil and dutasteride. Users joke about transplanting his facial hair and discuss the challenges of his condition compared to typical balding.

SCUBE3, a protein linked to hair growth in moles, was discovered over 25 years ago and is being developed by Amplifica for potential hair loss treatment. Concerns exist about SCUBE3's association with cancer, as it is a protein that promotes cell growth, which could potentially trigger cancer development if used for hair growth therapy.

A 22-year-old male experiencing diffuse thinning is using oral minoxidil and finasteride but notices his hair looks thin in sunlight. Suggestions include using hair products, considering topical minoxidil, addressing seborrheic dermatitis, and possibly trying dutasteride or a hair transplant.

Minoxidil was applied to a single miniaturized hair follicle over four months, resulting in less miniaturization but not yet terminal growth. The user used a 5% minoxidil solution, specifically the Regaine brand, and observed changes using a handheld WiFi microscope.

The conversation discusses hair loss treatments, mentioning minoxidil, finasteride, RU58841, VDPHL, GT20029, and follicle cloning as potential solutions. It also reveals that the discussion about PP405 was an April Fool's joke.

PP405 updates are seen as vague and lacking substance, causing frustration among users. Some users report positive effects from using minoxidil and dutasteride, while others remain skeptical about new treatments.

PP-405, a potential hair loss treatment, shows promise in stimulating dormant hair follicles and may help with various hair loss types. Current treatments like Minoxidil are still recommended as PP-405 is in early trials and may take years to become available.

A 27-year-old male with diffuse hair loss, including the donor area, did not respond to finasteride, dutasteride, or minoxidil. He suspects his hair loss may be linked to a mild connective tissue disorder, possibly affecting the structural support of hair follicles, rather than being purely hormonal.

PP405 increased hair density by 20% in 31% of participants, but results are considered underwhelming. Minoxidil and finasteride are seen as more effective treatments.

Hair cloning is seen as a distant and potentially less relevant solution for hair loss due to its high cost, invasiveness, and the advancement of other treatments like Minoxidil and finasteride. Many believe that by the time hair cloning becomes viable, other less invasive and more effective treatments will be available.

Hair cloning and new treatments like ET-02, Veradermics (vdphl01), and wound-induced hair neogenesis show promise but are not yet widely available. Current effective treatments include minoxidil, finasteride, and dutasteride, with early intervention being crucial for better outcomes.

PP405 is being discussed as a potential treatment for hair loss, with uncertainty about its effectiveness compared to existing treatments like finasteride, dutasteride, and minoxidil. There is cautious optimism, but its impact on hair transplants remains unclear.

A 34-year-old woman is seeking effective hair concealers for thinning hair, having tried various medications like spironolactone and oral minoxidil without success. Recommendations include Boldify hairline powder and products like Hairo or Kerablend.

Corticosterone inhibits GAS6, affecting hair follicle stem-cell activity, with potential implications for stress-related hair loss. Ashwagandha and Vitamin K are suggested for reducing cortisol, but their effectiveness is debated.

P-1075 is a more potent hair growth agent than Minoxidil, but it poses significant heart risks, making it unsafe for use. Despite promising results in macaques, concerns about its cardiotoxicity in rats have halted its development.